Jesse C Patterson
Overview
Explore the profile of Jesse C Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Merrick K, Kong Y, Izrael-Tomasevic A, Eng G, Handly E, et al.
Cell Rep Med
. 2024 Oct;
5(10):101778.
PMID: 39378883
5-fluorouracil (5-FU), a major anti-cancer therapeutic, is believed to function primarily by inhibiting thymidylate synthase, depleting deoxythymidine triphosphate (dTTP), and causing DNA damage. Here, we show that clinical combinations of...
2.
Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, et al.
Cell Death Dis
. 2024 Jul;
15(7):521.
PMID: 39039067
Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings. Identifying combination treatments to sensitize tumor cells and/or...
3.
Green B, Gamble L, Diggs L, Nousome D, Patterson J, Joughin B, et al.
Mol Cancer Res
. 2023 Sep;
21(12):1356-1365.
PMID: 37707375
Implications: Characterization of the tumor-immune microenvironment in HDGC underscores the potential for the immune system to shape the transcriptional profile of the earliest tumors, which suggests immune-directed therapy as a...
4.
Chen J, Merrick K, Kong Y, Izrael-Tomasevic A, Eng G, Handly E, et al.
bioRxiv
. 2023 May;
PMID: 37162991
5-fluorouracil (5-FU) is a successful and broadly used anti-cancer therapeutic. A major mechanism of action of 5-FU is thought to be through thymidylate synthase (TYMS) inhibition resulting in dTTP depletion...
5.
Patterson J, Varkaris A, Croucher P, Ridinger M, Dalrymple S, Nouri M, et al.
Cancer Res
. 2022 Nov;
83(2):219-238.
PMID: 36413141
Significance: Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.
6.
Patterson J, Goupil L, Thorner J
Biomolecules
. 2021 Oct;
11(10).
PMID: 34680163
Eukaryotes utilize distinct mitogen/messenger-activated protein kinase (MAPK) pathways to evoke appropriate responses when confronted with different stimuli. In yeast, hyperosmotic stress activates MAPK Hog1, whereas mating pheromones activate MAPK Fus3...
7.
Suarez-Lopez L, Kong Y, Sriram G, Patterson J, Rosenberg S, Morandell S, et al.
Front Immunol
. 2021 Mar;
11:607891.
PMID: 33708191
Chronic inflammation increases the risk for colorectal cancer through a variety of mechanisms involving the tumor microenvironment. MAPK-activated protein kinase 2 (MK2), a major effector of the p38 MAPK stress...
8.
Kong Y, Dreaden E, Morandell S, Zhou W, Dhara S, Sriram G, et al.
Nat Commun
. 2020 Aug;
11(1):4124.
PMID: 32807787
In response to DNA damage, a synthetic lethal relationship exists between the cell cycle checkpoint kinase MK2 and the tumor suppressor p53. Here, we describe the concept of augmented synthetic...
9.
Patterson J, Joughin B, Prota A, Muhlethaler T, Jonas O, Whitman M, et al.
Cell Syst
. 2019 Jul;
9(1):74-92.e8.
PMID: 31302152
There is an unmet need for new antimitotic drug combinations that target cancer-specific vulnerabilities. Based on our finding of elevated biomolecule oxidation in mitotically arrested cancer cells, we combined Plk1...
10.
Patterson J, Joughin B, van de Kooij B, Lim D, Lauffenburger D, Yaffe M
Cell Syst
. 2019 Feb;
8(2):163-167.e2.
PMID: 30797774
Although elevated levels of reactive oxygen species (ROS) have been observed in cancer cells and cancer cells aberrantly proliferate, it is not known whether the level of reactive oxygen species...